The SpaceX Dragon cargo spacecraft that ferried musclebound mice to the International Space Station and back can be seen at the top of this picture taken from the station on Dec. 20, 2019. NASA hide caption
The SpaceX Dragon cargo spacecraft that ferried musclebound mice to the International Space Station and back can be seen at the top of this picture taken from the station on Dec. 20, 2019.
In early December at the Kennedy Space Center in Florida, two anxious scientists were about to send 20 years of research into orbit.
"I feel like our heart and soul is going up in that thing," Dr. Emily Germain-Lee told her husband, Dr. Se-Jin Lee, as they waited arm-in-arm for a SpaceX rocket to launch.
A few seconds later the spacecraft took off, transporting some very unusual mice to the International Space Station, where they would spend more than a month in near zero gravity.
Ordinarily, that would cause the animals' bones to weaken and their muscles to atrophy. But Lee and Germain-Lee, a power couple in the research world, were hoping that wouldn't happen with these mice.
"It was worth waiting 20 years for," Lee said as the Falcon 9 rocket headed toward space. "And someday it may really help people," Germain-Lee added.
The couple hope that what they learn from these mice will lead to new treatments for millions of people with conditions that weaken muscles and bones. Among those who might eventually benefit: children with muscular dystrophy or brittle bone disease, cancer patients with muscle wasting, bedridden patients recovering from hip fractures, older people whose bones and muscles have become dangerously weak, and astronauts on long space voyages.
Dr. Emily Germain-Lee and Dr. Se-Jin Lee waited eagerly at Kennedy Space Center for a SpaceX rocket to launch their experimental mice into space in December. Courtesy of Jennifer Read hide caption
Dr. Emily Germain-Lee and Dr. Se-Jin Lee waited eagerly at Kennedy Space Center for a SpaceX rocket to launch their experimental mice into space in December.
For Lee and Germain-Lee, both professors at the University of Connecticut School of Medicine, the launch represented a high point in a partnership that began in the late 1970s.
"We met when I was 18 and we were biochem majors in college together," Germain-Lee said.
The Harvard undergraduates clicked. And in those early years, Emily had a teenager's big dreams about what she and Se-Jin might accomplish.
"Wouldn't that be amazing if one day we worked on some project together that had incredible meaning and helped people," she recalled thinking. "All that stuff."
The couple went to medical school together at Johns Hopkins in Baltimore.
She went on to become a pediatric endocrinologist who treated children with rare bone disorders. He added a Ph.D. to his M.D. and started a lab that studied muscle growth.
Along the way, they got married and had a son. And in the late 1990s, Se-Jin Lee got kind of famous for helping to create some bulked-up rodents known as "mighty mice."
The mouse on the right has been engineered to have four times the muscle mass of a normal lab mouse.
Lee showed me one when I visited his lab in 2006. It had been genetically engineered to have about four times the muscle mass of a normal mouse.
Lee had altered the animal's genes so it wouldn't produce a protein called myostatin. Ordinarily, myostatin limits the growth of muscles. Without it, you get the mouse version of Arnold Schwarzenegger.
"If you open up the mouse and actually look at the muscles it is really unbelievable," he told me. "These animals are almost getting to the point where they don't really look like mice." Lee thought his discovery might help people with diseases that weaken muscles. So he began looking for a drug that could block myostatin and duplicate the effects of genetic engineering.
Meanwhile, as Germain-Lee treated more and more children with bone diseases, she noticed that weak bones could lead to weak muscles.
"My bone patients don't escape muscle loss because they have long periods of time where they can't move or their whole lifetime where they're wheelchair bound," she said.
And because she also sees patients with diseases like muscular dystrophy, she realized it could work the other way. "Any muscle disease leads to weakness and any weakness leads to bone fragility eventually," Germain-Lee said.
At home, the couple spent many evenings discussing muscle, bone, her patients and his work on myostatin.
"Probably most people would think we're really odd," Germain-Lee said. "But it's given great meaning to our life."
Over the years, they realized that what many patients really needed was a way to simultaneously strengthen muscle and bone. And remarkably, they eventually identified a drug with the potential to do that.
It's a substance that affects not only myostatin, but also a protein called activin, which is involved in the growth of both muscle and bone. And it would bring together the parallel lines of research each scientist had been following for decades.
Germain-Lee wanted to test the drug on mice in her lab that developed a version of osteogenesis imperfecta, also known as brittle bone disease. "I said, oh my gosh I really have to try this, and Se-Jin said sure," she said. "And those were the first set of experiments we did together."
The experiments, published in 2015, were successful. The mice developed both stronger bones and bigger muscles. And the results helped inspire Lee to revive an idea he'd been pursuing for two decades. It involved astronauts.
"Astronauts in space have lots of health things that they need to be thinking about," he said, "but certainly at the top of that list would be muscle loss and bone loss.
Without gravity, astronauts can lose up to 20 percent of their muscle mass in less than two weeks, according to research by NASA. And as muscles atrophy, bones begin to weaken too.
So starting in the late 1990s, Lee had approached NASA about funding an experiment to see whether his mighty mice maintained their muscles in space. But his efforts to interest the agency in the project "failed miserably," he said.
That changed after the couple had moved to Hartford, where, in addition to their faculty posts at the University of Connecticut, Germain Lee holds an appointment at Connecticut Children's Medical Center and Lee works at The Jackson Laboratory.
And it was through The Jackson Laboratory that Lee got a chance to send his mighty mice to the International Space Station.
In late 2018, the Center for the Advancement of Science in Space, which manages the International Space Station, contacted The Jackson Laboratory about potential science projects. And Lee's new employer suggested the mighty mice.
Lee and Germain-Lee quickly assembled an experiment that included not only the bulked up rodents, but normal mice that would receive the drug that (on earth) builds both muscle and bone.
The mice, which had gone into orbit in December, were brought back to earth in early January. And since then, Lee and Germain-Lee have been hard at work analyzing what happened to the animals' muscles and bones.
It will take months to know for sure whether any of the mice were able to defy the usual effects of weightlessness. Also scientists rarely discuss experiments before they're published.
But the couple says preliminary results look promising.
Read more here:
Mighty Mice In Space May Help Disabled People On Earth : Shots - Health News - NPR
- genetic engineering summary | Britannica - September 13th, 2024
- The great gene editing debate: can it be safe and ethical? - BBC.com - September 13th, 2024
- Anti-biotechnology campaigners embrace classic crops, are suspicious of hybrid varieties and claim genetic modification violates nature. Heres a... - September 13th, 2024
- Will IL-11 Control Extend Human Life One Day? Early Results are Tantalizing - Securities.io - September 13th, 2024
- Viewpoint: As New Zealand edges toward relaxing its ban on gene edited foods, experts weigh in - Genetic Literacy Project - September 13th, 2024
- Farmers in Brazil and Argentina ramp up growing of genetically-modified drought tolerant wheat that can grow in subtropical regions - Genetic Literacy... - September 13th, 2024
- Scientist explains why we'll never have a real Jurassic Park - and people are crestfallen - indy100 - September 13th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021
- Gene editing, joke theft and manifesting - The Week UK - October 5th, 2021
- Opinion: Saving lives through real social justice - Agri-Pulse - October 5th, 2021
- Science, business and the humanities: CP Snow's 'Two Cultures' sixty years on - TheArticle - October 5th, 2021
- Probiotic Yeast Engineered To Produce Beta-Carotene - Technology Networks - April 17th, 2021
- In the US, Imminent Release of Genetically Modified Mosquitoes To Fight Dengue - The Wire Science - April 17th, 2021
- CRISPRoff: A New Addition to the CRISPR Toolbox - Technology Networks - April 17th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 17th, 2021
- Grammar of the Genome: Reading the Influence of DNA on Disease - Baylor University - April 17th, 2021
- We cannot let China set the standards for 21st century technologies | TheHill - The Hill - April 17th, 2021
- First GMO Mosquitoes to Be Released in the Florida Keys - Singularity Hub - April 17th, 2021
- Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations - BioSpace - April 17th, 2021
- AmunBio and NorthShore University to Advance Cancer Immunotherapy with Engineered Oncolytic Viruses - OncoZine - April 17th, 2021
- StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - BioSpace - April 17th, 2021
- ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com - April 17th, 2021
- EU's refusal to permit GMO crops led to millions of tonnes of additional CO2, scientists reveal - Alliance for Science - Alliance for Science - February 14th, 2021
- New species of fly named after Singanallur Tank - The Hindu - February 14th, 2021
- Son of Monarchs Pays Homage to the Beauty of Migration - Sierra Magazine - February 14th, 2021
- Podcast: TIME's 2020 Kid of the Year, Gitanjali Rao - All Together - Society of Women Engineers - February 14th, 2021
- Geoengineering: What could possibly go wrong? Elizabeth Kolbert's take, in her new book - Bulletin of the Atomic Scientists - February 14th, 2021
- An Introduction to PCR - Technology Networks - February 14th, 2021
- Science Talk - Evolution, cancer and coronavirus how biology's 'Theory of Everything' is key to fighting cancer and global pandemics - The Institute... - February 14th, 2021
- 22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with... - February 14th, 2021
- Aleph Farms and The Technion Reveal World's First Cultivated Ribeye Steak - PRNewswire - February 9th, 2021
- Researchers create rice that captures more CO2 with 30 percent more yield - FoodIngredientsFirst - February 9th, 2021
- Interview: Elizabeth Kolbert on why well never stop messing with nature - Grist - February 9th, 2021
- Is Biotechnology the Answer to a More Sustainable Beauty Industry? - Fashionista - February 9th, 2021
- New Jersey arts and entertainment news, features, and event previews. - New Jersey Stage - February 9th, 2021
- CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft... - February 9th, 2021
- Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic... - February 9th, 2021
- A new tool to investigate bacteria behind hospital infections - MIT News - February 9th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 9th, 2021
- Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization - GlobeNewswire - February 9th, 2021
- Global Lab-On-A-Chip Market Industry Perspective, Comprehensive Analysis, and Forecast 2027||Players-Perkin Elmer Corporation, IDEX, Thermo Fisher... - February 9th, 2021
- Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium - PharmiWeb.com - February 9th, 2021
- Global Bacterial and Plasmid Vectors Market Report 2020: Market is Expected to Recover and Reach $0520 Million in 2023 at a CAGR of 15.48% - Forecast... - January 12th, 2021
- mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry - TIME - January 12th, 2021